Biocon: IPO will evolve Syngene CRO into full manufacturing services firm

By Dan Stanton contact

- Last updated on GMT

Indian drugmaker Biocon is looking to spin out its CRO Syngene
Indian drugmaker Biocon is looking to spin out its CRO Syngene

Related tags: Initial public offering, Stock market

Indian CRO Syngene has received approval for its IPO prospectus paving the way to spin out from its parent company Biocon.

According to a letter filed with the Bombay Stock Exchange (BSE) last week, Bangalore-headquartered drugmaker Biocon is set to begin offering equity shares in its contract research organisation (CRO) Syngene International on July 27 for two days, after a Red Herring Prospectus* was approved by the Indian Government’s Registrar of Companies (ROC).

The news comes three months after Biocon announced it was looking to spin-out its CRO business through an initial public offering (IPO) some commentators speculated​ could raise up to 6bn rupees ($94 million).

The price per equity share has been fixed between 240 and 250 rupees ($3.8-$3.9m) and, in a statement, Managing Director Kiran Mazumdar-Shaw said the ROC’s approval “is an important milestone”​ for Syngene and the IPO process.

“We believe that Syngene has earned a global reputation in the area of integrated discovery and  development  services  for novel  small  molecules and biologics and are confident of the value proposition that the company offers.”

Syngene employs around 2,000 scientists and has over 90,000 sq ft of lab and manufacturing space, but the services firm is hoping to expand its capabilities and capacity through the IPO.

“We intend to evolve from a CRO into a Contract Research and Manufacturing Services (CRAMS) organisation with commercial-scale manufacturing capabilities, as we leverage our existing relationships with clients and provide forward integration on the discovery and development continuum,”​ the Red Herring Prospectus​ states.

This strategy see Syngene building a new commercial-scale facility in Mangaluru, which will make small molecules for innovator companies, while the firm is also in the process of expanding its large molecule manufacturing capabilities with a new unit in Bengaluru.

“We believe we are very well-positioned to benefit from the growth in the global CRAM’s market and see this listing a natural next step in our evolution expanding on other recent investments,”​ Syngene’s CEO Peter Bains said.

*A Red Herring Prospectus is a prospectus, which does not have details of either price or number of shares being offered, or the amount of issue.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 01-Jun-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars